Colgate-Palmolive Company (CL)
Colgate-Palmolive EPS Up, Revenue Lags
Consumer goods manufacturer Colgate-Palmolive (CL -5.19%) reported mixed fourth-quarter and full-year 2024 earnings on Friday, Jan. 31. Adjusted earnings per share (EPS) for Q4 rose to $0.91, surpassing Wall Street consensus estimates of $0.89.
Colgate-Palmolive (CL) Q4 Earnings Surpass Estimates
Colgate-Palmolive (CL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.87 per share a year ago.
Colgate-Palmolive's stock slips on weaker-than-expected guidance despite Q4 profit beat
Colgate-Palmolive's CEO noted that the company hit an “exciting milestone,” but it wasn't enough to lift the stock premarket.
Colgate-Palmolive sees weaker annual sales on demand slowdown
Toothpaste maker Colgate-Palmolive forecast annual sales below Wall Street expectations after missing quarterly sales estimates on Friday, hurt by weak demand in North America and Latin America for its household products.
Colgate-Palmolive Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Colgate-Palmolive Company CL will release earnings results for its fourth quarter before the opening bell on Friday, Jan. 31, 2025.
Colgate-Palmolive stock analysis: overvalued ahead of earnings
The Colgate-Palmolive stock price remains in a deep correction as investors wait for the fourth-quarter results. CL has plunged by over 17%, bringing its market cap to about $73 billion.
Colgate Stock Sees Strong Momentum Pre-Q4 Earnings: Time to Invest?
CL's Q4 results are expected to reflect gains from pricing, funding-the-growth and other productivity initiatives, supporting strong business momentum.
Colgate-Palmolive (CL) Earnings Expected to Grow: Should You Buy?
Colgate-Palmolive (CL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Colgate Advances 13% in a Year: To Buy or Not to Buy the Stock?
CL's solid pricing strategies and premium innovation drive growth, but macroeconomic challenges and currency headwinds warrant cautious optimism.
Crest, Colgate lawsuits target fluoride in kids' toothpaste, mouth rinse
Procter & Gamble and Colgate-Palmolive are among the defendants in six new lawsuits targeting the sale of toothpaste and mouth rinse for young children because the products contain fluoride, which can be harmful if swallowed.
3 Defensive Picks to Add Stability to Your Portfolio
As of January 9, 2025, the New York Fed's model to predict the likelihood of a recession suggests there is a 29% chance the U.S. will enter a recession sometime in 2025. This figure is down sharply from just two years ago, when the model—which makes predictions based yield spreads between 3-month T-bills and 10-year Treasury bonds—gave a 70% chance of a recession.
3 Ultra-Reliable Dividend King Stocks That Should Increase Their Payouts to All-Time Highs in 2025, Even if There's a Stock Market Sell-Off
When the S&P 500 is roaring higher, it's easy to overlook the benefits of investing in hihg-quality, dividend-paying companies. After all, a 2%, 3%, or even 4% dividend yield doesn't look impressive relative to a 23.3% gain -- which we saw from the S&P 500 in 2024.
